CA2978807A1 - Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines - Google Patents

Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines Download PDF

Info

Publication number
CA2978807A1
CA2978807A1 CA2978807A CA2978807A CA2978807A1 CA 2978807 A1 CA2978807 A1 CA 2978807A1 CA 2978807 A CA2978807 A CA 2978807A CA 2978807 A CA2978807 A CA 2978807A CA 2978807 A1 CA2978807 A1 CA 2978807A1
Authority
CA
Canada
Prior art keywords
dihydroimidazo
methoxy
quinazolin
morpholin
ylpropoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978807A
Other languages
English (en)
French (fr)
Inventor
Ningshu Liu
Carol Pena
Michael Jeffers
Isabelle GENVRESSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Healthcare Pharmaceuticals Inc
Original Assignee
Bayer Pharma AG
Bayer Healthcare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Healthcare Pharmaceuticals Inc filed Critical Bayer Pharma AG
Publication of CA2978807A1 publication Critical patent/CA2978807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2978807A 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines Abandoned CA2978807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130547P 2015-03-09 2015-03-09
US62/130,547 2015-03-09
PCT/EP2016/054728 WO2016142313A1 (en) 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Publications (1)

Publication Number Publication Date
CA2978807A1 true CA2978807A1 (en) 2016-09-15

Family

ID=55484986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978807A Abandoned CA2978807A1 (en) 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Country Status (18)

Country Link
US (1) US20180042929A1 (enExample)
EP (1) EP3268005A1 (enExample)
JP (1) JP2018512403A (enExample)
KR (1) KR20180013850A (enExample)
CN (1) CN107683138A (enExample)
AU (1) AU2016231260A1 (enExample)
BR (1) BR112017019190A2 (enExample)
CA (1) CA2978807A1 (enExample)
CL (1) CL2017002284A1 (enExample)
EA (1) EA201791975A1 (enExample)
HK (1) HK1250645A1 (enExample)
IL (1) IL254168A0 (enExample)
MA (1) MA43840A (enExample)
MX (1) MX2017011607A (enExample)
PH (1) PH12017501644A1 (enExample)
SG (1) SG11201707239WA (enExample)
TN (1) TN2017000385A1 (enExample)
WO (1) WO2016142313A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3068324A1 (en) * 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
CN111500587A (zh) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒
EP4143569B1 (en) * 2020-05-01 2026-07-29 Mayo Foundation for Medical Education and Research Methods for treating endometrial cancer
WO2022140467A1 (en) * 2020-12-21 2022-06-30 Samson Pharma, Llc Topical compositions and methods of treating skin diseases and conditions with such compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618489A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EA201201414A8 (ru) * 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014191938A1 (en) * 2013-05-31 2014-12-04 Novartis Ag Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer

Also Published As

Publication number Publication date
MA43840A (fr) 2018-11-21
SG11201707239WA (en) 2017-10-30
JP2018512403A (ja) 2018-05-17
BR112017019190A2 (pt) 2018-04-24
MX2017011607A (es) 2018-04-10
WO2016142313A1 (en) 2016-09-15
HK1250645A1 (zh) 2019-01-11
EA201791975A1 (ru) 2018-03-30
KR20180013850A (ko) 2018-02-07
TN2017000385A1 (en) 2019-01-16
PH12017501644A1 (en) 2018-03-12
US20180042929A1 (en) 2018-02-15
CL2017002284A1 (es) 2018-05-18
AU2016231260A1 (en) 2017-09-21
CN107683138A (zh) 2018-02-09
EP3268005A1 (en) 2018-01-17
IL254168A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
US10226469B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas
AU2017203474B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US20180042929A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168582A1 (en) Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HK1220121B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
NZ615502B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HK1194995B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HK1194995A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
NZ712033B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210909

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: T-6-6-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240903